INTRAVENOUS (IV) IBUPROFEN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

With the ongoing opioid epidemic, there is significant focus on adoption of non-narcotic options for managing pain. In comparison to opioid painkillers, intravenous (IV) ibuprofen provides an appealing non-addictive alternative that carries less risk of side effects or potential for abuse. Regulators and medical organizations have also been promoting greater use of non-opioid therapies. As a result, healthcare providers and patients have become increasingly receptive to non-opioid options like intravenous (IV) ibuprofen. It addresses pain in a reliable, consistent manner without the medical and social risks tied to opioids. With sustained policy and clinical emphasis on curbing opioid prescriptions, the preference for effective non-opioid therapies is enhancing the attractiveness of intravenous ibuprofen. Many people view it as an important tool in improving post-procedure and post-surgery pain management while avoiding opioids whenever clinically appropriate. This makes intravenous (IV) ibuprofen well-positioned for stronger market growth.

• Cumberland Pharmaceuticals Inc. 
• Hyloris Pharmaceuticals SA
• Grifols, S.A.
• Recordati Rare Diseases Inc.
• XGEN PHARMACEUTICALS DJB, Inc.
• AFT Pharmaceuticals
• Laboratorios Valmorca
• SGPharma Pvt. Ltd.
• Wellona Pharma
• Delex Pharma
• Hikma Pharmaceuticals PLC